The antiplatelet agent revacept prevents the increase of systemic thromboxane A₂ biosynthesis and neointima hyperplasia

Sara Alberti¹,², Qianqian Zhang³,⁸, Ilaria D'Agostino¹,²,⁸, Annalisa Bruno¹,², Stefania Tacconelli¹,², Annalisa Contursi¹,², Simone Guarnieri³, Melania Dovizio¹,², Lorenza Falcone³, Patrizia Ballerini³,⁴, Götz Münch⁵, Ying Yu⁶,⁷ & Paola Patrignani¹,²

Neointima hyperplasia is a crucial component of restenosis after coronary angioplasty. We have hypothesized that enhanced generation of platelet-derived thromboxane (TX)A₂ in response to vascular damage plays a critical role in neointimal hyperplasia and that antiplatelet agents may mitigate it. In cocultures of human platelets and coronary artery smooth muscle cells (CASMC), we found that platelets induced morphologic changes and enhanced the migration of CASMC. The exposure of platelets to Aspirin [an inhibitor of cyclooxygenase (COX)-1] reduced the generation of TXA₂ and prevented the morphological and functional changes induced by platelets in CASMC. Platelet-derived TXA₂ induced COX-2 and enhanced prostaglandin (PG)E₂ biosynthesis in CASMC, a known mechanism promoting neointimal hyperplasia. COX-2 induction was prevented by different antiplatelet agents, i.e., Aspirin, the TP antagonist SQ29,548, or Revacept (a dimeric soluble GPVI-Fc fusion protein). The administration of the novel antiplatelet agent Revacept to C57BL/6 mice, beginning three days before femoral artery denudation, and continuing up to seven days after injury, prevented the increase of the systemic biosynthesis of TXA₂ and reduced femoral artery intima-to-media area and the levels of markers of cell proliferation and macrophage infiltration. Revacept might serve as a therapeutic agent for percutaneous coronary angioplasty and stent implantation.

1Department of Neuroscience, Imaging and Clinical Science, “G. D'Annunzio” University, Chieti, Italy. 2CAST (Center for Advanced Studies and Technology) (Ex CeSi-MeT), “G. D'Annunzio” University, Via dei Vestini 31, 66100 Chieti, Italy. 3International Peace Maternity and Child Health Hospital of China Welfare Institution, Shanghai, China. 4Department of Innovative Technologies in Medicine and Dentistry, “G. D’Annunzio” University, Chieti, Italy. 5AdvanceCOR GmbH, Martinsried, Germany. 6Shanghai Institute for Biological Sciences, Chinese Academy of Science, Shanghai, China. 7Department of Pharmacology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China. 8These authors contributed equally: Sara Alberti, Qianqian Zhang and Ilaria D'Agostino. *email: ppatrignani@unich.it
their phenotype from contractile to synthetic, which promotes the extracellular matrix synthesis\(^1\). These events constitute the neointimal hyperplasia, which contributes to postprocedural lumen loss. In animal models, peak neointimal growth is observed 28 days following bare-metal stent placement, whereas in humans, it is identified at 6–12 months\(^1\).

COX-2, an inducible enzyme that mediates the generation of prostanoids in inflammation\(^3\), plays a role in restenosis progression\(^12\). COX-2 is markedly upregulated in vascular inflammation, such as atherosclerosis and balloon-injured arteries\(^3,14\). Pharmacological inhibition or specific deletion of COX-2 in VSMC reduces vascular neointima hyperplasia in response to mechanical injury\(^12,14\). COX-2 mediates these effects by enhancing the generation of prostaglandin (PG)E\(_2\) that contributes to vascular restenosis pathogenesis through the activation of the PGE\(_2\) receptor subtype EP\(_3\)α/β and its signaling pathways cAMP/protein kinase A and phosphatidylinositol 3-kinase\(^2\). Moreover, genetic disruption of microsomal PGE\(_2\) synthase-1 attenuates neointima formation after vascular injury\(^15\). However, the pharmacological inhibition of vascular COX-2 by the use of selective COX-2 inhibitors (named coxibs) is not recommended in this setting for their cardiovascular hazard\(^16\).

In the early phase of restenosis, platelets are the chief cellular players\(^17\) through their adhesion to VSMC, at the site of the vascular damage, facilitated by subendothelial collagen exposure, and to the release of soluble factors, such as lipid mediators derived from arachidonic acid (especially TXA\(_2\))\(^18\).

Revacept, a novel antiplatelet agent in clinical development, is a soluble form of the platelet GPVI receptor that binds specifically to collagen at vascular damage sites, thus inhibiting platelet adhesion and aggregation without affecting general hemostasis in humans\(^19\). Using fluorescence-labeled glycoprotein V1 (GPVI)-Fc in ApoE-deficient [ApoE\(^{−/−}\)-mice, fed with a 1.25% cholesterol diet over 16 weeks], the mechanical-induced carotid injury was associated with increased GPVI-Fc-binding to injured carotids compared to intact carotids\(^20\).

In cocultures of human platelets and coronary artery smooth muscle cells (CASMC), we addressed the hypothesis that platelet-derived TXA\(_2\) is the trigger of the induction of COX-2-derived-PGE\(_2\), a pathway involved in the development of neointimal hyperplasia\(^2\). Then, we tested whether Revacept attenuates neointimal formation and prevents enhanced systemic TXA\(_2\) biosynthesis in mice after arterial injury. Our findings suggest that the inflammatory response to vascular damage after coronary angioplasty might be mitigated by avoiding platelet-vessel wall interaction and preventing enhanced TXA\(_2\) biosynthesis using Revacept.

**Methods**

**Coculture experiments with human coronary smooth muscle cells (CASMC) and washed human platelets isolated from venous blood.** CASMC (at passage 5) ( Lonza Walkersville Inc, MD, USA) were cultured in flasks coated with collagen type I from rat tail (BD Bioscience Discovery Labware, Bedford MA, USA), at 37 °C in a humidified atmosphere of 5% CO\(_2\) in air, in the culture system BulletKit (Lonza) containing SmBM (Basal Medium) and SmGM-2 (Smooth Muscle Cell Growth Medium-2) SingleQuots supplements and 5% fetal bovine serum (FBS). Then, CASMC (0.8 × 10\(^5\) cells) were seeded in a six-multwell plate coated with collagen type I from rat tail in 2 ml of culture system containing 5% FBS. After 48 h (h), the medium was changed with Dulbecco's modified Eagle's medium (DMEM) containing 0.75% bovine serum albumin (BSA) (Sigma-Aldrich, Milan, Italy) and 1% polymyxin-B sulphate (Sigma-Aldrich) and human washed platelets (0.5 × 10\(^8\) cells in 100 μl), freshly isolated from concentrated buffy coats (obtained from the blood bank of SS Annunziata Hospital, Chieti, Italy), local Ethics Committee of “G. d'Annunzio” University of Chieti-Pescara. Separate experiments (n) were performed using different buffy coats.

**Immunofluorescence.** CASMC (0.8 × 10\(^5\) cells) were cultured alone or cocultured with platelets (0.5 × 10\(^8\)) for 8 h, then, cells were washed twice with phosphate buffer solution (PBS) pH 7.4 and fixed in acetone/methanol (40:60) for 20 min at room temperature. Cells were blocked with a filtrated solution of BSA (3%) in PBS for 30 min at room temperature. Cells were incubated overnight at 4 °C with polyclonal antibodies anti-COX-1 or anti-COX-2 (1:200, Cayman Chemical, Ann Arbor, MI, USA) and anti-α-SMA (1:200, Santa Cruz Biotechnology, Dallas, Texas, USA). Cells were then washed three times with PBS and incubated with the secondary antibodies, donkey anti-rabbit Alexa Fluor 488 and goat anti-mouse Alexa Fluor 546 (1:1000, Life Technologies, Waltham, MA, USA) for 1 h at room temperature. Cells were washed three times with PBS and incubated for 5 min with 4′,6-diamidino-2-phenylindole (DAPI; 300 nM, Sigma Aldrich) to label nuclear DNA. Finally, cells were washed and mounted in slides with Diamond antifade mounting media (Life Technologies). Slides were observed with a Zeiss LSM 510 meta microscope (Carl Zeiss, Jena, Germany), and confocal images were analyzed using Zeiss LSM 5 series software (Carl Zeiss).

**Pharmacological treatments in vitro.** The selective COX-1 inhibitor Aspirin (acetylsalicylic acid, ASA, Sigma-Aldrich), the selective COX-2 inhibitor Rofecoxib (Witega Laboratorien, Berlin, Germany), and the TP antagonist SQ 29,548 (Sigma-Aldrich) were dissolved in dimethyl sulfoxide (DMSO, Sigma-Aldrich). Rofecoxib (0.3 μM) or SQ 29,548 (10 μM), or DMSO were added to CASMC for 30 min before the addition of platelets. In other experiments, platelets were pretreated with Aspirin (100 μM) or DMSO before the incubation with CASMC; briefly, platelet-rich plasma was incubated with Aspirin (100 μM) or DMSO for 30 min at room temperature; then platelets were isolated\(^21\), washed twice, and either cultured alone or cocultured with CASMC for 20 h. Finally, Revacept\(^18\) or vehicle (PBS/4% mannitol/1% sucrose (Sigma Aldrich)) were added to CASMC for 1 h, and then, the medium was changed, replaced with the platelet cell suspension, and incubated for 20 h.
CASMC or platelets cultured alone or cocultured were lysed in 1% Triton and 1 mM phenylmethylsulphonyl fluoride (Sigma-Aldrich) and stored at −80 °C until assayed by Western blot. In some experiments, the supernatants were collected, centrifuged at 700×g for 5 min, and stored at −80 °C until assayed for prostanoid levels.

Migration assay. Cell migration of confluent CASMC cultured alone or with platelets, pretreated, or not with Aspirin, was evaluated by scrape wounding assay, as previously described. Briefly, after 20 h of platelet-CASM cocultures, platelets were washed away. Cells, seeded on a 6-multiwell dish, were scraped using a 200 μl pipette tip, simulating a wound, incubated in DMEM 0.75% BSA, and monitored periodically by light microscope up to 24 h. Image processing was performed using Image J 1.44 software (NIH, USA), and the percentage of cell-free area and cell covered area were calculated using the analysis particle tool.

Biochemical analyses. TXB2 and 6-keto-PGF1α [the nonenzymatic hydrolysis product of TXA2 and prostacyclin (PGI2), respectively], PGD2, PGE2, and PGF2α were measured in cell culture media by previously described and validated immunoassay techniques.

Western blot analyses. Cell lysates were mixed with sodium dodecyl sulfate (SDS) (Sigma-Aldrich) sample buffer and heated to 95 °C for 5 min. Proteins (15 μg) were analyzed by SDS polyacrylamide gel electrophoresis (SDS-PAGE). Anti-COX-2, anti-COX-1 polyclonal antibodies (1:1000, Cayman Chemical), GAPDH polyclonal antibody (1:1000, Santa Cruz Biotechnology), or anti-β-actin polyclonal antibody (1:1000, Santa Cruz Biotechnology) were used. Quantification of optical density (OD) of different specific bands was carried out using Alliance 4.7 and Alliance 1 D software (UVTtec, Cambridge, UK) and normalized to the OD of β-actin or GAPDH.
Animals. Male C57BL/6 mice (8–10 weeks old, n = 20) were purchased from Shanghai SLAC Laboratory Animal Co., Ltd. (Shanghai, China). All animals were maintained and used according to the veterinary guidelines of the Institutional Animal Care and Use Committee of the Institute for Nutritional Sciences, Chinese Academy of Sciences, Shanghai (China). Experimental protocols were approved by the Institutional Animal Care and Use Committee of the Institute for Nutritional Sciences, Chinese Academy of Sciences, Shanghai (China). Every effort was made to minimize the number of animals used and any pain or discomfort experienced by the animals.
In vivo study design and surgical procedures. The femoral artery wire injury model was described previously elsewhere. A contralateral (left femoral arteries) sham surgery was used as a control by performing the protocol without the wire injury. Right femoral arteries were exposed by blunt dissection and subjected to denudation. Briefly, arteries were exposed by blunted dissection, dilated by topical application of one drop of 1% lidocaine hydrochloride (Sigma-Aldrich) and transverse arteriotomy was performed in the muscular branch; a straight spring wire (0.38 mm in diameter, COOK, Bloomington, IN, USA) was carefully inserted into the femoral artery for more than 5 mm toward the iliac artery and left in place for 1 min to denude and dilate the artery. Then, the wire was removed, and blood flow in the femoral artery was restored. Animals were randomly assigned to two different treatment groups. One group (n = 10) received Revacept, the protein obtained by fusing the extracellular domain of GPVI with the human immunoglobulin (IgG) Fc domain (at the dose of 2 mg/kg/day), via tail-vein injection, for three days before bilateral femoral artery denudation was performed. The treatment was continued up to day 10. Control group mice (n = 10) were treated with recombinant human IgG1 Fc (at the dose of 2 mg/kg/day) (Sino Biological Inc., China) via tail-vein injection. The compounds were dissolved in a solution of PBS/mannitol(4%)/sucrose(1%). The concentration of Revacept and Fc were selected based on previously published studies. For all surgical procedures, the animals were ventilated with isoflurane and oxygen to maintain anesthesia throughout the experiment, and anesthetic depth was assessed by observing the reflex responses to paw pinches. Histology and immunohistochemistry were performed on specimens collected at day 32 (i.e., 28 days after injury). Moreover, 24 h-urine collections were performed on day 0 (baseline), day 3, day 7, and 32 (i.e., before injury and 3 and 28 days after injury, respectively) for the assessment of 11-dehydro-TXB2 (TXM) levels, as a marker of the systemic TXA2 biosynthesis, mainly derived from the activity of platelet COX-1.

Figure 3. Effects of platelets on CASMC migration. (A) Human CASMC (0.8 × 10^5 cells) were cultured alone or cocultured with human platelets (0.5 × 10^8) (pretreated or not with Aspirin, ASA, 100 µM) for 20 h and cell migration of confluent cells was evaluated at different time-points (up to 24 h) by scrape wounding assay, using an inverted microscope and a digital camera (original magnification ×10), the dashed lines indicate the starting position of the cell migration occurring toward the center of the wound; % of covered area values are reported as mean ± SEM, n = 3 (separate experiments), the scale bar is of 100 µm. Each experimental condition, % covered area was significantly different (P < 0.01) at each time-point versus time 0 (using two-way ANOVA, Dunnett's multiple comparisons test), not shown. At 4 h, **P < 0.01, CASMC alone versus CASMC + PLT and CASMC + PLT-ASA; at 8 h, **P < 0.01, CASMC alone versus CASMC + PLT and CASMC + PLT-ASA; at 12 h, **P < 0.01, CASMC alone versus CASMC + PLT and CASMC + PLT-ASA, §P < 0.01, CASMC + PLT versus CASMC + PLT-ASA; at 24 h, **P < 0.01, CASMC alone versus CASMC + PLT and CASMC + PLT-ASA, §P < 0.01, CASMC + PLT versus CASMC + PLT-ASA (using two-way ANOVA, Tukey's multiple comparisons test). (B) The results of cell migration obtained at 24 h are shown.
Histology and immunohistochemistry. At the end of the in vivo experiments (i.e., 28 days after surgery), all animals were euthanized and intracardially perfused with 10 ml of 4% paraformaldehyde (PFA, Sigma Aldrich). Femoral arteries were fixed with 4% PFA for 10–15 min and then embedded in paraffin. Paraaffin-embedded Sections (7 μm) were stained with hematoxylin and eosin (HE, Sigma-Aldrich), and the intima-to-media area (I/M) ratio was assessed as previously described. Briefly, the intimal area is the area encircled by the internal elastic lamina minus lumen area. The medial area is calculated as the area encircled by the external elastic lamina minus intima area. The intima-to-media ratio was calculated as the intimal area divided by the medial area. For immunohistochemistry, tissue sections were incubated with primary antibodies against Ki67 (1:500, Abcam, Cambridge, UK), CD68 (1:200, AbD Serotec, Kidlington, UK), followed by incubation with horseradish peroxidase(HRP)-conjugated secondary antibody [anti-rabbit IgG (Cell Signaling Technology, Leiden, The Netherlands)]1:2000; anti-rat IgG (ProteinTech Group, Rosemont, IL, USA) 1:2000. After three washings with PBS, samples underwent 3'-Diaminobenzidine (DAB, Sigma-Aldrich) staining, hematoxylin restaining, dehydration, and cover glass mounting. Slides were observed with a Zeiss Axiosvision microscope (Carl Zeiss) and Image J 1.44 software was used for the analysis.

Assessment of urinary levels of TXM. Two-hundred μl of 24 h-urine collection samples were extracted, and the levels of the TXM, i.e., an enzymatic urinary metabolite of TXB2, were measured by previously validated immunoassay techniques. The urinary TXM levels were corrected for creatinine excretion and reported as ng/mg of creatinine.

Statistical analysis. All values were reported as mean ± SD (standard deviation) in the text, while shown as mean ± SEM (standard error of the mean) in the Figures; the n values (indicating the number of separate experiments) were reported in Figure legends. Statistical analysis among two groups was performed by Student's t-test; for 3 and more groups, ANOVA (one-way or two-way) or Mixed-effects analysis for repeated measures (when some values were missed) were carried out using GraphPad PRISM software (version 8.00 for Windows; GraphPad, San Diego, CA, USA). P values < 0.05 were considered statistically significant.

Results
Effects of platelets on CASMC phenotype and morphology in vitro. The changes induced by platelets on the morphology and the phenotype of the CASMC were assessed using confocal microscopy by the labeling of COX-1 (a constitutive protein) and α-SMA (typical of a contractile phenotype). CASMC cultured alone appeared as spindle-shaped cells (Fig. 1A). The co-incubation with platelets led to epithelioid cell morphology, yielding a cobblestone pattern (Fig. 1B) associated with the downregulation of α-SMA vs. CASMC cultured alone (Fig. 1C,D and Supplementary Fig. 1); these changes describe the induction of the synthetic phenotype of vascular smooth muscle cells. COX-2 expression was induced in CASMC cocultured with platelets (Fig. 1D and Supplementary Fig. 1). The downregulation of α-SMA and upregulation of COX-2 induced by platelets in CASMC were confirmed by Western blot analysis (Fig. 2A–D). In contrast, CASMC COX-1 expression was not affected by their coculture with platelets (Fig. 2C,E).

Platelets enhanced the migratory capacity of CASMC. Cell migration of CASMC cultured alone or with platelets for 20 h was evaluated by scrape wounding assay. As shown in Fig. 3A,B, platelets enhanced the migration of CASMC. CASMC cultured with platelets that were pretreated with Aspirin (to cause a selective inhibition of platelet-COX-1 activity and TXA2 generation) showed a significantly lower migratory capacity versus CASMC cultured with platelets untreated with Aspirin, at 8–24 h (Fig. 3A,B).

Prostanoid biosynthesis in CASMC-platelet cocultures. In platelets cultured alone, TXB2 was the primary product of arachidonic acid metabolism (1014 ± 817 pg/ml) (Fig. 4A) while PGE2, PGF2α, and PGD2 were minor products of COX-1 activity (all < 250 pg/ml, not shown). In CASMC cultured alone, PGE2 (Fig. 4A) and 6-keto-PGF1α (not shown) were the most abundant prostanoids (3903 ± 3335 and 1310 ± 1271 pg/ml, respectively). In the coculture of platelets and CASMC, PGE2 and TXB2 were significantly increased (Fig. 4A). 6-keto-PGF1α did not significantly change in CASMC-platelet cocultures versus CASMC cultured alone (not shown). To verify the COX-1 or COX-2 origin of the increased biosynthesis of TXB2 and PGE2 in the coculture of CASMC and platelets, we assessed the impact of the exposure of platelets to Aspirin which was washed away before the incubation with CASMC (to target only platelet COX-1) or Rofecoxib (a selective COX-2 inhibitor). As shown in Fig. 4A, the increase of TXB2 detected in platelet-CASMC cocultures was entirely prevented by the treatment of platelets with Aspirin, suggesting that enhanced TXB2 derived from platelets. This is further sustained by Rofecoxib inability to affect TXB2 production in the coculture (Fig. 4A). Rofecoxib completely prevented the increased production of PGE2, measured in platelet-CASMC cocultures, implying that COX-2 induction in CASMC played a central role in enhanced PGE2 biosynthesis (Fig. 4A). PGE2 levels detected in the coculture medium were significantly reduced when aspirinated platelets were incubated with CASMC (Fig. 4A).

Effect of aspirin on platelet-induced COX-2 expression in CASMC. As shown in Fig. 4B,C, the pretreatment of platelets with Aspirin attenuated the capacity of platelets to induce COX-2 in CASMC. These results suggest that platelets induced COX-2-dependent PGE2 via an Aspirin sensitive mechanism.

Effect of TXA2 receptor (TP) blockage on COX-2 induction in platelet-CASMC coculture. We tested the role of TXA2 in the induction of COX-2 in CASMC exposed to platelets. To this aim, we used the
Figure 4. Effects of platelets on prostanoid generation and COX-2 expression of CASMC. (A) Levels of PGE$_2$ and TXB$_2$ in the conditioned medium of CASMC and platelets cultured alone, or cocultured for 20 h, assessed by immunoassays; the effect of Rofecoxib (Rofe, 0.3 µM) or aspirinated platelets (ASA, 100 µM was added during platelet isolation and then washed away) was assessed. **$P<0.01$, *$P<0.05$; n = 3–4 (separate experiments) (using one-way ANOVA, Tukey's multiple comparisons test). (B,E) The effect of ASA (100 µM) or of the TP antagonist SQ 29,548 (SQ, 10 µM) on COX-2 expression in cocultures of CASMC and platelets, was assessed by Western Blot. (F,G) CASMC were cultured alone or cocultured with platelets in the presence of Revacept (Reva, 40 µg/ml) or vehicle (PBS/4% mannitol/1% sucrose) and COX-2 levels were analyzed by Western blot; interleukin (IL)-1β was used as positive control. (C,E,G) COX-2 protein bands were quantified, and the optical density (OD) was calculated using laser densitometry and normalized to the OD of GAPDH or β-actin; data are reported as % of control (CASMC cultured alone), mean ± SEM. (C) **$P<0.01$ versus CASMC and §$P<0.05$ versus CASMC + PLT(ASA), n = 3 (separate experiments); (E) **$P<0.01$ versus all other conditions, n = 4 (separate experiments); (G) **$P<0.01$ versus all other conditions, except CASMC-IL1β, §$P<0.01$ versus all other conditions, except CASMC-vehicle-PLT, n = 3 (separate experiments); all analyses were conducted using one-way ANOVA and Tukey's multiple comparisons test.
selective TP antagonist SQ 29,548. As shown in Fig. 4D,E, TP blockage mitigated the induction of COX-2 in CASMC by the interaction with platelets. These results show that platelet-derived TXA₂ is the trigger of COX-2 induction in CASMC.

Effect of the antiplatelet agent Revacept on COX-2 induction in CASMC-platelet cocultures. Vascular smooth muscle cells synthesize and secrete collagen³³, contributing to the interaction with platelets and their activation. Thus, we tested whether Revacept, which affects the binding of platelets to collagen binding sites¹⁹, may prevent the induction of COX-2 in CASMC. As shown in Fig. 4F and G, Revacept mitigated platelet capacity to induce COX-2 in CASMC.

Revacept prevented the increase of systemic TXA₂ biosynthesis in response to injury in mice. We used the femoral artery wire injury model²⁵,²⁶ in C57BL/6 mice to verify the occurrence of platelet activation in response to vascular damage by assessing the urinary levels of TXM, an enzymatic metabolite of TXB₂, that is a marker of the systemic biosynthesis of TXA₂, mainly derived from activated platelets³⁸,³⁹. Moreover, we studied whether the administration of Revacept (2 mg/kg/day) to mice prevented the increase of TXA₂ biosynthesis in response to vascular injury as compared with mice treated with recombinant human IgG1 Fc (2 mg/kg/day) (control group). The experimental design of the study is reported in Fig. 5A.

At baseline, urinary TXM levels were comparable in the two groups of mice (Fc-control: 1.2 ± 0.6 ng/mg creatinine; Revacept: 1.3 ± 0.5 ng/mg creatinine; n = 10) (not shown). As shown in Fig. 5B, in mice treated with
Fc-control, the urinary levels of TXM significantly \((P < 0.05)\) increased at 3 days after injury versus the values detected before vascular damage. At 28 days after injury (remodeling phase), TXM values were comparable to those measured at pre-injury condition (Fig. 5B). These results show that platelet activation occurs in response to damage because of the endothelial denudation and subintimal component exposure. In contrast, in the remodeling phase, platelet function returns to the baseline condition.

The administration of Revacept, 2 mg/kg daily, prevented the increase of TXM levels \((P < 0.05)\) versus Fc-control at three days after vascular injury (Fig. 5B).

**Revacept reduced the expression of markers of vascular neointima proliferation and macrophage infiltration.** In the remodeling phase (at 28 days after injury), we studied the expression levels of proteins, which are markers of macrophages infiltration and cell proliferation, such as CD68 and Ki67, respectively, in paraffin-embedded section of femoral arteries. The vascular injury was associated with an increased expression of CD68 (Fig. 6A,C) and Ki67 (Fig. 6B,D). The administration of Revacept mitigated the enhanced expression of these markers (Fig. 6A–D).

Altogether these results show that the inhibition of platelet activation in response to vascular injury by Revacept translates into the prevention of the proliferative and inflammatory events which feature the remodeling phase.

**Revacept reduced vascular neointima formation in response to injury in mice.** In this model of neointima hyperplasia induced by mechanical damage, we evaluated the effect of the administration of Revacept on the arterial media thickness in paraffin-embedded sections of femoral arteries. As reported in Fig. 7A and B, 28 days after arterial injury, Revacept caused a significant \((P < 0.05)\) average reduction of I/M ratio by 41.36% versus the Fc-control group.
Discussion

Platelet activation represents an early response to vascular damage34. Platelets adhere to extracellular matrix proteins exposed in the injured vasculature and release numerous soluble mediators, including TXA2. It acts in an autocrine or paracrine manner to stimulate adjacent platelets, thus generating more TXA2 and amplifying other agonist action6. TXA2 also enhances lymphocyte and macrophage functions35–37 and stimulates the biosynthesis of extracellular matrix proteins38. For all these actions, TXA2 might play a crucial role in initiating and accelerating intimal hyperplasia development.

In a femoral artery wire injury model25,26 in C57BL/6 mice, we assessed the time-course of the systemic biosynthesis of TXA2 by measuring the urinary levels of TXM, an enzymatic metabolite of TXB2, which is mainly derived from activated platelets28,29. Our results show a rapid increase in the systemic biosynthesis of TXA2 in response to vascular damage, which returned to pre-injury values at a later phase on neointimal hyperplasia (i.e., 28 days after injury). The enhanced generation of platelet TXA2 may induce numerous cellular events that contribute to neointimal hyperplasia. By performing coculture experiments between platelets and CASMC, we have shown that platelet-derived TXA2 contributes to COX-2 induction and enhanced PGE2 generation by CASMC. We exploited Aspirin capacity to cause an irreversible inhibition of platelet COX-1-dependent TXA2 generation, persisting when the drug is washed away. The incubation of CASMC with Aspirin-treated platelets mitigated the induction of COX-2. Comparable results were obtained by TP blockage.

Zhang et al.12 have previously shown that COX-2-derived PGE2 promotes vascular neointimal hyperplasia in response to mechanical injury. Moreover, COX-2-derived PGE2 regulates polarization and directional migration of vascular smooth muscle cells via the activation of the PGE2 receptor subtype EP3α/β32,33. Here, we show that platelets enhanced the migration of CASMC; this response was mitigated by the selective inhibition of platelet COX-1 by Aspirin.

Collectively these results suggest that platelets are activated by the interaction with vascular smooth muscle cells and extracellular matrix proteins, such as collagen, and release TXA2, which contributes to enhanced COX-2-dependent PGE2 biosynthesis. Our findings imply the effectiveness of pharmacological inhibition of platelet TXA2 biosynthesis by Aspirin to restrain the development of injury-induced vascular neointimal hyperplasia. However, the results of clinical trials with Aspirin suggest a small reduction in the restenosis after coronary angioplasty but a significant reduction in the frequency of ischemic complications39. The weakness of these studies is that different doses of Aspirin were used; furthermore, the drug capacity to cause a virtually complete suppression of platelet COX-1-dependent TXB2 biosynthesis was not verified40. The possible beneficial effect of
low-dose Aspirin in patients undergoing percutaneous coronary intervention through the inhibition of vascular inflammation triggered by activated platelets remains to be verified in appropriate clinical studies.

Aspirin exerts antiplatelet effects by inhibiting TXA₂-dependent aggregation responses and amplifying these responses by released ADP⁴¹. Conversely, Revacept combines inhibitory effects on both collagen-mediated platelet adhesion and subsequent aggregation at the site of vascular injury⁴². These concomitant inhibitory effects on platelet function by Revacept are proper to limit the consequences of vascular damage. We show that the administration of Revacept mitigated vascular neo-intima hyperplasia in a femoral artery injury mouse model. This effect was associated with reduced vascular expression of markers of macrophages infiltration and cell proliferation. Revacept administration prevented the rapid increase of the systemic biosynthesis of TXA₂ after vascular injury derived mainly from platelets⁴³,⁴⁰. These data support the hypothesis that platelet activation in response to vascular injury represents an early event contributing to the inflammatory response involved in vascular remodeling.

Interestingly, the interaction of platelets with CASMC in vitro led to morphological changes typical of a synthetic phenotype with downregulation of α-SMA and upregulation of COX-2. These changes were associated with the enhanced migratory capacity of CASMC. Revacept prevented the induction of COX-2 by the interaction of platelets with CASMC.

Collectively our findings sustain the distinct roles of platelets beyond their fundamental participation in primary hemostasis. As previously shown in cocultures with myofibroblasts, platelet-derived TXA₂ induces morphological changes and enhances their capacity to proliferate and migrate, thus contributing to tissue fibrosis⁴³. Moreover, we have shown that the interaction of platelets with colon cancer cells translates into the overexpression of COX-2, a hallmark of malignancy, and the induction of marker genes of epithelial-mesenchymal transition⁴⁳. Inhibition of platelet-cancer cell interactions by Revacept prevented platelet-induced COX-2 induction and changes of epithelial-mesenchymal transition markers⁴⁵.

The main limitation of the present study is that the effect of Revacept on neointimal formation was not compared with Aspirin given alone or co-administered with Revacept. Low-dose Aspirin could cause additional efficacy by preventing the amplification of platelet response induced by other platelet agonists, in addition to collagen. This is an important point that needs to be explored in a specific study.

In conclusion, we show that Revacept, an inhibitor of the binding of platelet collagen receptors (mainly GPVI) to collagen exposed in areas of damaged endothelium⁴⁶, constrains the release of TXA₂ from activated platelets. These distinct effects played by Revacept make it a promising therapeutic strategy to prevent restenosis in patients with coronary artery disease treated with percutaneous transluminal coronary angioplasty and stent implantation. Importantly, Revacept was found to affect platelet function in the absence of bleeding complications⁴⁷. A phase II randomized, double blind trial (www.clinicaltrials.gov; NCT03312855) is ongoing to assess the efficacy and safety of Revacept in patients undergoing elective percutaneous coronary intervention (ISAR-PLASTER Trial⁴⁸).

Received: 27 April 2020; Accepted: 13 November 2020
Published online: 08 December 2020

References

1. Weintraub, W. S. The pathophysiology and burden of restenosis. Am. J. Cardiol. 100, 3K–9K (2007).
2. Nieswandt, B. & Watson, S. P. Platelet-collagen interaction: Is GPVI the central receptor? Blood 102, 449–461 (2003).
3. Ricciotti, E. & FitzGerald, G. A. Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol. 31, 986–1000 (2011).
4. Hanasaki, K., Nakano, T. & Arita, H. Receptor-mediated mitogenic effect of thromboxane A2 in vascular smooth muscle cells. Biochem. Pharmacol. 40, 2535–2542 (1990).
5. Yokota, T. et al. Thromboxane A2 receptor stimulation promotes closure of the rat ductus arteriosus through enhancing neointima formation. PLoS ONE 9, e94895 (2014).
6. Smyth, E. M. Thromboxane and the thromboxane receptor in cardiovascular disease. Clin. Lipidol. 5, 209–219 (2010).
7. Feng, X. et al. Thromboxane A2 activates YAP/TAZ protein to induce vascular smooth muscle cell proliferation and migration. J. Biol. Chem. 291, 18947–18958 (2016).
8. Cheng, Y. et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296, 539–541 (2002).
9. Ciabattoni, G. et al. E-prostanoid 3 receptor. Am. J. Cardiol. 113, 104–114 (2013).
10. Grosse, T., Yu, Y. & FitzGerald, G. A. Emotion recollected in tranquility: lessons learned from the COX-2 saga. Annu. Rev. Med. 61, 17–33 (2010).
11. Yang, H. M. et al. Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation 110, 301–308 (2004).
12. Grosser, T., Fries, S. & FitzGerald, G. A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J. Clin. Investig. 116, 4–15 (2006).
13. Chandrasekar, B. & Tanguay, J. F. Platelets and restenosis. Am. J. Cardiol. 35, 555–562 (2000).
14. Kearney, D., Byrne, A., Crean, P., Cox, D. & Fitzgerald, D. J. Optimal suppression of thromboxane A2 formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor. J. Am. Coll. Cardiol. 43, 526–531 (2004).
15. Ungerer, M. et al. Novel antiplatelet drug revacept (Dimeric Glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans. Circulation 123, 1891–1899 (2011).
20. Schönberger, T. et al. The immunoadhesin glycoprotein VI-Fc regulates arterial remodelling after mechanical injury in ApoE−/− mice. Cardiovasc. Res. 80, 131–137 (2008).

21. Dovizio, M. et al. Pharmacological inhibition of platelet-tumor cell cross-talk prevents platelet-induced overexpression of cyclooxygenase-2 in HT29 human colon carcinoma cells. Mol. Pharmacol. 84, 25–40 (2013).

22. Terzuoli, E. et al. Bradykinin B2 receptor contributes to inflammatory responses in human endothelial cells by the transactivation of the fibroblast growth factor receptor FGFR-1. Int. J. Mol. Sci. 6, 9pitE2638 (2016).

23. Sacco, A. et al. Platelet-specific deletion of cyclooxygenase-1 ameliorates dextran sulfate sodium-induced colitis in mice. J. Pharmacol. Exp. Ther. 370, 416–426 (2019).

24. Patrignani, P. et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prosta glandin endoperoxide synthases. J. Pharmacol. Exp. Ther. 271, 1705–1712 (1994).

25. Sata, M. et al. A mouse model of vascular injury that induces rapid onset of medial cell apoptosis followed by regenerative hyperplasia. J. Mol. Cell Cardiol. 32, 2097–2104 (2000).

26. Roque, M. et al. Mouse model of femoral artery denudation injury associated with the rapid accumulation of adhesion molecules on the luminal surface and recruitment of neutrophils. Arterioscler. Thromb. Vasc. Biol. 20, 335–342 (2000).

27. Schüpke, S. et al. The GPVI–Fc fusion protein revacept reduces thrombus formation and improves vascular dysfunction in ath erosclerosis without any impact on bleeding times. PLoS ONE 8, e71193 (2013).

28. Ciabattoni, G. et al. Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man. Biochim. Biophys. Acta 992, 66–70 (1989).

29. Catella, F. & FitzGerald, G. A. Paired analysis of urinary thromboxane B2 metabolites in humans. Thromb. Res. 47, 647–656 (1987).

30. Louis, S. F. & Zahradka, P. Vascular smooth muscle cell motility: From migration to invasion. Exp. Clin. Cardiol. 15, e75-e85 (2010).

31. Li, S. et al. Innate diversity of adult human arterial smooth muscle cells: cloning of distinct subtypes from the internal thoracic artery. Circ. Res. 89, 517–525 (2001).

32. Ross, R. & Glomset, J. A. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 180, 1332–1339 (1973).

33. Rocnik, E. F., Chan, B. M. & Pickering, J. G. Evidence for a role of collagen synthesis in arterial smooth muscle cell migration. J. Clin. Investig. 101, 1889–1898 (1998).

34. Gawaz, M., Langer, H. & May, A. E. Platelets in inflammation and atherogenesis. J. Clin. Investig. 115, 3378–3384 (2005).

35. Leung, K. H. & Mühle, E. Prostaglandin modulation of development of cell mediated immunity in culture. Nature 288, 597–600 (1980).

36. Ceuppens, J. L., Vertessen, S., Deckmyn, H. & Vermeylen, J. Effects of thromboxane A2 on lymphocyte proliferation. Cell. Immunol. 90, 458–463 (1985).

37. Thomas, D. W. et al. Proinflammatory actions of thromboxane receptors to enhance cellular immune responses. J. Immunol. 171, 6389–6395 (2003).

38. Bruggeman, L. A., Horiga, E. A., Horikishi, S., Ray, P. E. & Klotman, P. E. Thromboxane stimulates synthesis of extracellular matrix proteins in vitro. Am. J. Physiol. 261, F488–F494 (1991).

39. Smith, S. C. Jr. et al. American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty); Society for Cardiac Angiography and Interventions. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)—executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 103, 3019–3041 (2001).

40. Steinhibl, S. R. & Berger, P. B. Aspirin following PCI: Too much of a good thing? Eur. Heart J. 30, 882–884 (2009).

41. Weiss, H. J. The discovery of the antiplatelet effect of aspirin: a personal reminiscence. J. Thromb. Haemost. 1, 1869–1875 (2003).

42. Schipke, S. et al. Revacept, a novel inhibitor of platelet adhesion, in patients undergoing elective PCI—design and rationale of the randomized ISAR-PLASTER Trial. Thromb. Haemost. 119, 1539–1545 (2019).

Author contributions
Concept or design of the work: S.A., P.P., Y.U.; performed the acquisition, analysis or interpretation of data for the work: S.A., Q.Z., A.B., I.D.A., L.F., S.T., A.C.; draft the work or revising it critically for important intellectual content: P.P., Y.Y., M.D., P.B., G.M., S.G. All authors approve the final version to be published and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Funding
The study was supported by a MIUR Grant (ex 60%) to PP.

Competing interests
All authors declare none conflict of interest except Götz Münch, who is CEO of AdvanceCOR GmbH.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-77934-x.

Correspondence and requests for materials should be addressed to P.P.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
